Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study (vol 25, pg e1930, 2020)

被引：1
|
作者：
Frass, Michael
Lechleitner, Peter
Gruendling, Christa
Pirker, Claudia
Grasmuk-Siegl, Erwin
Domayer, Julian
Hochmair, Maximilian
Gaertner, Katharina
Duscheck, Cornelia
Muchitsch, Ilse
Marosi, Christine
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Manchanda, Raj K.
Schrott, Andrea
Burghuber, Otto
机构：
来源：
ONCOLOGIST | 2021年 / 26卷 / 03期
关键词：
D O I：
10.1002/onco.13693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E523 / E523
页数：1
相关论文
共 50 条
  • [31] A randomized, double-blind, placebo-controlled phase II study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer (NSCLC).
    Von Pawel, Joachim
    Hadler, Dietrich
    Fox, Tara
    Wang, Qiang
    Greenberg, Jonathan
    Beckman, Robert A.
    Krzakowski, Maciej Jerzy
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)
    Scagliotti, G.
    Vynnychenko, I.
    Ichinose, Y.
    Park, K.
    Kubota, K.
    Blackhall, F. H.
    Pirker, R.
    Galiulin, R.
    Ciuleanu, T.
    Sydorenko, O.
    Dediu, M.
    Papai-Szekely, Z.
    Banaclocha, N. Martinez
    Mccoy, S.
    Yao, B.
    Hei, Y. J.
    Spigel, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [33] TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)
    Quoix, Elisabeth A.
    Nemunaitis, John J.
    Burzykowski, Tomasz
    Bastien, Berangere
    Lacoste, Gisele
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)
    Ramalingam, S. S.
    Maitland, M.
    Frankel, P.
    Argiris, A. E.
    Koczywas, M.
    Gitlitz, B.
    Espinoza-Delgado, I.
    Vokes, E. E.
    Gandara, D. R.
    Belani, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    He, Yong
    Li, Li
    Jiang, Liyan
    Wang, Yubo
    Zhao, Yizhuo
    Zhang, Xiaoju
    Wu, Guoming
    Zhou, Xiangdong
    Sun, Jianguo
    Bai, Jun
    Ren, Biyong
    Tian, Kun
    Xu, Zhi
    Xiao, Hualiang
    Zhou, Qi
    Han, Rui
    Chen, Hengyi
    Wang, Haidong
    Yang, Zhenzhou
    Gao, Chan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study (vol 25, pg 2088, 2019)
    Thatcher, Nicholas
    Goldschmidt, Jerome H.
    Thomas, Michael
    Schenker, Michael
    Pan, Zhiying
    Paz-Ares Rodriguez, Luis
    Breder, Valery
    Ostoros, Gyula
    Hanes, Vladimir
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 3193 - 3193
  • [37] Psychometric Evaluation of Quality of Life in a Three-Arm, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-Onset Seizures (EXIST-3)
    Franz, D.
    de Vries, P.
    Curatolo, P.
    Nabbout, R.
    Fan, J.
    Neary, M.
    Herbst, F.
    Sully, K.
    Brohan, E.
    Lawson, J.
    ANNALS OF NEUROLOGY, 2017, 82 : S282 - S282
  • [38] Psychometric Evaluation of Quality of Life in a Three-Arm, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Everolimus as Adjunctive Therapy in Patients with Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-Onset Seizures (EXIST-3)
    Franz, David N.
    de Vries, Petrus J.
    Curatolo, Paolo
    Nabbout, Rima
    Fan, Jenna
    Neary, Maureen
    Herbst, Fabian
    Sully, Kate
    Brohan, Elaine
    Lawson, John
    ANNALS OF NEUROLOGY, 2017, 82 : S159 - S160
  • [39] Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study
    Vansteenkiste, Johan
    Zielinksi, Marcin
    Linder, Albert
    Dahabre, Jubrail
    Esteban, Emilio
    Malinowski, Wojciech
    Jassem, Jacek
    Passlick, Bernward
    Lehmann, Frederic
    Brichard, Vincent G.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S334 - S335
  • [40] ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Novello, Silvia
    Mellemgaard, Anders
    Kaiser, Rolf
    Douillard, Jean-Yves
    Orlov, Sergei
    Krzakowski, Maciej
    Von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Griebsch, Ingolf
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1207 - S1207
12345